知搜-全球专利检索

  1. 登录
  2. 注册

搜索结果

430 条记录 (耗时 0.017 秒)

    Plasma expander and blood substitute
    71.
    发明授权
    Plasma expander and blood substitute 失效
    血浆扩张器和血液替代品

    公开(公告)号：US5571801A

    公开(公告)日：1996-11-05

    申请号：US446520

    申请日：1995-05-22

    申请人： Paul E. Segall ,  Harold D. Waitz ,  Hal Sternberg ,  Judith M. Segall

    发明人： Paul E. Segall ,  Harold D. Waitz ,  Hal Sternberg ,  Judith M. Segall

    IPC分类号： A61K33/00 ,  A01N1/02 ,  A61K9/00 ,  A61K31/00 ,  A61K31/19 ,  A61K31/718 ,  A61K33/06 ,  A61K33/10 ,  A61K33/14 ,  A61K35/14 ,  A61P7/08 ,  A61K31/715 ,  A01N1/00 ,  A61K31/72 ,  A61K47/36

    CPC分类号： A01N1/0221 ,  A01N1/0284 ,  A61K33/10 ,  A61K33/14 ,  A61K9/0026 ,  Y10S514/832 ,  Y10S514/833

    摘要： An artificial plasma-like substance having at least one water soluble polysaccharide oncotic agent selected from the group consisting of high molecular weight hydroxyethyl starch, low molecular weight hydroxyethyl starch, dextran 40 and dextran 70, and albumin which is buffered by lactate and has a pre-administration pH of between 5 and 6.5 is disclosed. Also disclosed is an artificial plasma-like solution having at least two water soluble polysaccharide oncotic agents one of which is eliminated from the circulation slowly and the other of which is eliminated from the circulation quickly. Supplimentation of the plasma-like solution with certain ions is described. A system for administration of the plasma-like solution to a subject wherein the system comprises a first and second solution each having particular buffers is described. The plasma-like solution including cryoprotective adducts is also disclosed. The use of the plasma-like solution in organ transplant, novel chemotherapy procedures, and tissue, organ and organism cryopreservation are also disclosed.

    摘要翻译： 一种人造等离子体物质，其具有选自高分子量羟乙基淀粉，低分子量羟乙基淀粉，葡聚糖40和葡聚糖70中的至少一种水溶性多糖成分剂和由乳酸盐缓冲的白蛋白， 公开了5至6.5的给药pH。 还公开了一种人造血浆样溶液，其具有至少两种水溶性多糖成核剂，其中一种缓慢地从循环中消除，另一种从溶液中快速除去。 描述了具有某些离子的等离子体状溶液的补充。 描述了一种用于将血浆样溶液施用于受试者的系统，其中系统包括每个具有特定缓冲液的第一和第二溶液。 还公开了包括冷冻保护加合物的等离子体样溶液。 还公开了在器官移植中使用血浆样溶液，新颖的化疗程序以及组织，器官和有机体的低温保存。

    Defoaming composition
    72.
    发明授权
    Defoaming composition 失效
    消泡组合物

    公开(公告)号：US5275822A

    公开(公告)日：1994-01-04

    申请号：US806581

    申请日：1991-12-12

    申请人： William Valentine ,  William K. Valentine

    发明人： William Valentine ,  William K. Valentine

    IPC分类号： A61K9/20 ,  A61K9/00 ,  A61K9/16 ,  A61K31/7004 ,  A61K31/7016 ,  A61K31/715 ,  A61K31/718 ,  A61K31/80 ,  A61K47/36 ,  A61P1/00 ,  A61P1/04 ,  B01D19/04 ,  A61K31/695 ,  A61K47/26

    CPC分类号： A61K47/36 ,  A61K31/80 ,  A61K9/0056 ,  A61K9/1623 ,  A61K9/1652 ,  B01D19/0404 ,  Y10S514/82 ,  Y10S514/96

    摘要： A defoaming or antifoaming composition comprises a free flowing granular combinate of 50 to 90 weight percent of a water soluble carbohydrate-based agglomerate selected from the group consisting of maltodextrin agglomerates, maltodextrin/dextrose co-agglomerates, dextrose agglomerates, maltodextrin/sucrose co-agglomerates, maltodextrin/fructose co-agglomerates, sucrose agglomerates, fructose agglomerates, mannitol agglomerates, sorbitol agglomerates, agglomerates of hydrolyzed cereal solids, and agglomerates of corn syrup solids and about 10 to 50 weight percent of a liquid, nonaqueous, defoaming or antifoaming composition such as simethicone, hydrocarbon-based oils or silicone oils. The composition may be combined with one or more suitable excipients and prepared as a unit dosage in the form of a compressed tablet, filled capsule, packet, or granule for various defoaming applications.

    摘要翻译： 消泡或消泡组合物包含50-90重量％的选自麦芽糖糊精聚集体，麦芽糖糊精/葡萄糖共附聚物，葡萄糖附聚物，麦芽糖糊精/蔗糖共附聚物的水溶性碳水化合物基附聚物的自由流动的颗粒组合物 麦芽糖糊精/果糖共附聚物，蔗糖附聚物，果糖聚集体，甘露醇附聚物，山梨醇附聚物，水解谷物固体的附聚物和玉米糖浆固体的附聚物和约10至50重量％的液体，非水，消泡或消泡组合物 作为二甲硅油，烃基油或硅油。 组合物可以与一种或多种合适的赋形剂组合，并以用于各种消泡应用的压缩片剂，填充胶囊，包装或颗粒形式的单位剂量制备。

    COMPOSITIONS AND METHODS FOR METABOLIC HEALTH
    73.
    发明公开
    COMPOSITIONS AND METHODS FOR METABOLIC HEALTH 审中-公开

    公开(公告)号：US20240335403A1

    公开(公告)日：2024-10-10

    申请号：US18742991

    申请日：2024-06-13

    申请人： Glucose Health, Inc.

    发明人： Murray Stewart Fleming

    IPC分类号： A61K31/192 ,  A61K31/555 ,  A61K31/718 ,  A61P3/06 ,  A61P3/10

    CPC分类号： A61K31/192 ,  A61K31/555 ,  A61K31/718 ,  A61P3/06 ,  A61P3/10

    摘要： Compositions for managing post-prandial metabolic changes, including glycemic and lipid responses, and related methods of manufacture and use. A composition for attenuating post-prandial glycemic response (GR) and lipid response (LR) reduces risk of chronic metabolic diseases. Certain ingredients of the composition include resistant dextrin, corosolic acid, and chromium(III) picolinate, which may be combined together using a wet agglomeration or a dry mixing step. The agglomerated or dryly mixed ingredients may then be intimately dry blended with a flavored matrix to improve palatability. The composition may be consumed before, during, and/or after a meal for attenuation of post-prandial rise in plasma glucose, triglyceride levels, and cholesterol levels and reduction of risk of chronic metabolic diseases.